August 27,The Drug Clinical Trial Registration and Information Disclosure Platform shows，Amgen has registered aMaridebart Cafraglutide（AMG 133）TreatmentHeart Failure with Preserved or Mildly Reduced Ejection FractionPhase III Clinical Trial in Combination with Obesity（MARITIME-HF）。Screenshot source:Drug Clinical Trial Registration and Information Disclosure Platform
This is aRandomized, Double-blind, Placebo-controlled, Phase III Study, Aiming toEvaluate the efficacy and safety of Maridebart Cafraglutide on mortality and morbidity in participants with heart failure with preserved or mildly reduced ejection fraction and obesity. The dosing regimen is once every four weeks.（Q4W）, Subcutaneous injection.The study will be conducted at 116 institutions worldwide, with participants in China.120 People`, International Proposed Enrollment`5,056 people. The primary endpoint isDue to CV death orHeart Failure（HF）Time to the first occurrence of a composite endpoint.Maridebart Cafraglutide It was developed by Amgen.Subcutaneous Injection of GLP-1R Agonist/GIPR Antagonist。The international top journal Nature once published an article introducingNext-Generation Weight Loss Drugs, including Amgen'sMaridebart Cafraglutide。
Screenshot source:Corporate Website
In addition to the heart failure indication launched this time, Amgen...Maridebart Cafraglutide Also LayoutAtherosclerosis(Phase III Clinical Trial)、Obesity(Phase III Clinical Trial)、Type 2 Diabetes(Phase III Clinical Trial)And a variety of other indications.
Insight database shows that currently, there are 5 GLP-1 related drugs undergoing research for heart failure indications globally, with no products yet approved for marketing. Among them,TirzepatideThe fastest progress has already been made.Submission of a listing application for heart failure with preserved ejection fraction combined with obesity indication, other successors from Amgen（Maridebart Cafraglutide）, Innovent（Mashiduo Peptide）, Hengrui（HRS9531）And Huadong Medicine（Poterepatide）。
Screenshot source:Corporate Website
Cover Source: Corporate LogoDisclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.PR Article Coordination: WeChat insightxbSubmissionWeChat: insightxb; Email: insight@dxy.cn
Diversified functions, traceable data……Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
